Obesity最新文献

{"title":"Perceptions of anti-obesity medications among people with obesity and healthcare providers in the US: Findings from the OBSERVE Study","authors":"Lee M. Kaplan,&nbsp;Kimberly Gudzune,&nbsp;Jamy Ard,&nbsp;Rekha Kumar,&nbsp;Nadia N. Ahmad,&nbsp;Hong Kan,&nbsp;Tracy J. Sims,&nbsp;Jiat Ling Poon,&nbsp;Kristen King-Concialdi,&nbsp;Kathleen Beusterien,&nbsp;Sheila Drakeley,&nbsp;Julia P. Dunn,&nbsp;Scott Kahan,&nbsp;the OBSERVE Study","doi":"10.1002/oby.24290","DOIUrl":"10.1002/oby.24290","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>The objective of this study was to understand the perceptions of and drivers/barriers to antiobesity medication (AOM) use among people with obesity (PwO) and health care providers (HCPs) in the United States.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>In 2022, PwO and HCPs completed cross-sectional surveys that included questions on perceptions of obesity management and AOMs. Data were analyzed using descriptive statistics.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Survey participants (1007 PwO and 474 HCPs) emphasized the effectiveness of lifestyle change and the patient's responsibility to address obesity. PwO reported a willingness to take newly approved AOMs long term. HCPs believed that their patients would adhere to AOMs long term if they experienced success. Both PwO and HCPs perceived an increased effectiveness of a multimodal approach to combining AOMs with HCP-guided lifestyle intervention. Potential barriers to long-term use of AOMs for both groups included concerns regarding long-term side effects and outcomes, costs and insurance coverage, and perception of AOMs that do not align with treatment of a chronic disease.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>PwO and HCPs are interested in new AOM options, but educational gaps remain as a barrier to recommended multimodal chronic care. Ongoing education that includes the known effectiveness and safety data of newer AOMs and pending outcome trials could improve shared decision-making in obesity care.</p>\u0000 </section>\u0000 </div>","PeriodicalId":215,"journal":{"name":"Obesity","volume":"33 6","pages":"1076-1086"},"PeriodicalIF":4.2,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/oby.24290","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144029965","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Scarce and unpredictable, yet obesogenic: modeling the impact of food insecurity on adiposity in mice","authors":"Alessandro Bartolomucci,&nbsp;John R. Speakman","doi":"10.1002/oby.24295","DOIUrl":"10.1002/oby.24295","url":null,"abstract":"","PeriodicalId":215,"journal":{"name":"Obesity","volume":"33 6","pages":"1022-1024"},"PeriodicalIF":4.2,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144004208","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of metabolic phenotype changes on the development of chronic kidney disease: Panasonic cohort study 17","authors":"Junya Hironaka,&nbsp;Hiroshi Okada,&nbsp;Tetsuro Kusaba,&nbsp;Hanako Nakajima,&nbsp;Emi Ushigome,&nbsp;Masahide Hamaguchi,&nbsp;Kazushiro Kurogi,&nbsp;Hiroaki Murata,&nbsp;Naoki Yoshida,&nbsp;Masato Ito,&nbsp;Michiaki Fukui","doi":"10.1002/oby.24293","DOIUrl":"10.1002/oby.24293","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>This study investigated how changes in metabolic phenotype, defined by obesity and metabolic health, impact chronic kidney disease (CKD) development in a large cohort.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A retrospective cohort study analyzed health data collected between 2011 and 2021 from 84,729 Panasonic Holdings Corporation (formerly Panasonic Corporation) employees aged ≥40 years. Metabolic phenotypes were classified as metabolically healthy with no obesity (MHNO), metabolically healthy with obesity (MHO), metabolic abnormalities with no obesity (MANO), and metabolic abnormalities with obesity (MAO). Changes in metabolic phenotype over 3 years and their association with CKD development were assessed using Cox proportional hazards models adjusted for confounding variables.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>During a mean follow-up of 5.1 years, a total of 12,172 of participants (14.4%) developed CKD. Transitioning from MHO to MHNO and from MAO to MANO did not reduce CKD risk compared to each stable group. In contrast, participants in the MANO-to-MHNO and MAO-to-MHO groups significantly lowered CKD risk relative to each stable group, with hazard ratios of 0.86 (95% CI: 0.77–0.96) and 0.83 (95% CI: 0.67–1.02), respectively. The same results were observed when a rapid decline in renal function was used as the outcome.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The improvement of metabolic profile might outweigh weight reduction in CKD risk.</p>\u0000 </section>\u0000 </div>","PeriodicalId":215,"journal":{"name":"Obesity","volume":"33 6","pages":"1176-1183"},"PeriodicalIF":4.2,"publicationDate":"2025-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144063771","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rapid response to behavioral/pharmacological obesity treatments for binge-eating disorder predicts better clinical outcomes","authors":"Janet A. Lydecker,&nbsp;Ralitza Gueorguieva,&nbsp;Carlos M. Grilo","doi":"10.1002/oby.24292","DOIUrl":"10.1002/oby.24292","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>The objective of this study was to examine rapid response and its prognostic significance in participants with binge-eating disorder (BED) and obesity in a randomized clinical trial testing behavioral and pharmacological obesity treatments for BED.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A total of 136 participants were randomly assigned (balanced 2 × 2 factorial) to 16-week behavioral and/or pharmacological (naltrexone/bupropion) obesity interventions. Masked assessments occurred monthly throughout treatment and at posttreatment.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Rapid response (≥65% reduction in frequency of binge-eating episodes after 1 month of treatment), observed in 55% (<i>n</i> = 75/136) of participants, was unrelated to baseline sociodemographic and clinical characteristics. Rapid response was more common in behavioral therapy than not and in naltrexone/bupropion than placebo. Rapid response was associated with binge-eating remission. Mixed models revealed that rapid response was associated with greater reductions in binge-eating frequency, eating-disorder psychopathology, percent weight loss, and metabolic variables (total cholesterol, glycated hemoglobin A1c) at posttreatment. Rapid response effects on outcomes did not vary by treatment.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>In a randomized clinical trial testing behavioral and pharmacological obesity treatments for BED with co-occurring obesity, rapid response was a robust prognostic indicator of binge-eating remission and significantly better behavioral, psychological, and metabolic outcomes. Non-rapid response to behavioral and pharmacological obesity treatments could signal a need to switch to alternative treatments.</p>\u0000 </section>\u0000 </div>","PeriodicalId":215,"journal":{"name":"Obesity","volume":"33 6","pages":"1067-1075"},"PeriodicalIF":4.2,"publicationDate":"2025-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144049307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to Swoap et al.","authors":"Gwang-woong Go,&nbsp;Wooki Kim","doi":"10.1002/oby.24301","DOIUrl":"10.1002/oby.24301","url":null,"abstract":"","PeriodicalId":215,"journal":{"name":"Obesity","volume":"33 6","pages":""},"PeriodicalIF":4.2,"publicationDate":"2025-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144061151","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Functional mobility and pain are improved for 6 years after adolescent bariatric surgery","authors":"Neil Thivalapill,&nbsp;Todd M. Jenkins,&nbsp;Thomas H. Inge,&nbsp;Changchun Xie,&nbsp;Anita P. Courcoulas,&nbsp;Carroll M. Harmon,&nbsp;Michael A. Helmrath,&nbsp;Stephanie Sisley,&nbsp;Marc P. Michalsky,&nbsp;Justin R. Ryder,&nbsp;Teen-Longitudinal Assessment of Bariatric Surgery (Teen-LABS) consortium","doi":"10.1002/oby.24285","DOIUrl":"10.1002/oby.24285","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>The long-term durability of improvements in functional mobility and musculoskeletal pain for adolescents after metabolic and bariatric surgery (MBS) is unknown.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We used the Teen-Longitudinal Assessment of Bariatric Surgery (Teen-LABS) study to determine the change in mobility and pain among adolescents who underwent MBS. From standardized 400-m walk tests, we analyzed walk time, heart rate (HR) parameters, and musculoskeletal pain.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The mean walk time improved from 383 s (95% CI: 368–399) prior to surgery to 351 s (95% CI: 330–372) by 6 years. The mean resting HR was 90 beats per minute (bpm; 95% CI: 87–93) preoperatively and decreased to 80 bpm (95% CI: 76–84) by 6 years. The risk of any musculoskeletal pain decreased from 37.2% (95% CI: 25.5%–48.9%) to 11.0% (95% CI: 4.3%–17.6%) by 6 years. Mediation analysis revealed that the effect of time since surgery on walk time, resting HR, and HR recovery occurred through a weight-dependent mechanism. For posttest HR and HR difference, there was both a significant weight-dependent and weight-independent mechanism. The effect of surgery on the risk of musculoskeletal pain occurred through a weight-independent mechanism.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Adolescents who underwent MBS experienced significant, durable improvement in mobility and pain, despite weight regain. Our models suggest that improvements may occur through a weight-independent mechanism.</p>\u0000 </section>\u0000 </div>","PeriodicalId":215,"journal":{"name":"Obesity","volume":"33 6","pages":"1126-1135"},"PeriodicalIF":4.2,"publicationDate":"2025-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/oby.24285","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144056480","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unraveling the obesity paradox in polytrauma patients: survival benefit specifically in individuals with obesity class I","authors":"Hui-Tzung Luh,&nbsp;Tsung-Hung Wu,&nbsp;Lu-Ting Kuo,&nbsp;Shyr-Chyr Chen,&nbsp;Chin-Hua Su,&nbsp;Shu-Yu Tsao,&nbsp;Sung-Tsang Hsieh,&nbsp;Dar-Ming Lai,&nbsp;Chien-Chang Lee","doi":"10.1002/oby.24282","DOIUrl":"10.1002/oby.24282","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>The “obesity paradox” suggests that higher BMI values might be protective in certain conditions. However, it is controversial in polytrauma patients, with different studies presenting varying results.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A total of 1234 polytrauma patients were categorized by World Health Organization Asia-Pacific BMI classifications. Primary outcomes were 30- and 365-day all-cause mortality. Secondary outcome was length of hospital stay. Inverse probability of treatment weighting was performed to minimize baseline bias. Cox proportional hazards models we used to assess the impact of BMI on mortality.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The 30-day mortality rates were 7.5%, 9.0%, 6.7%, 2.4%, and 2.6% for patients with underweight (&lt;18.5 kg/m²), normal weight (18.5–22.9 kg/m²), overweight (23.0–24.9 kg/m²), obesity class I (25.0–29.9 kg/m²), and obesity class II (&gt;30.0 kg/m²), respectively. The 365-day mortality rates were 12.5%, 15.0%, 12.6%, 7.5%, and 7.7%, respectively. Only obesity class I was associated with a significantly lower risk of 30-day (hazard ratio [HR] = 0.19, 95% CI: 0.06–0.66; <i>p</i> = 0.00864) and 365-day mortality (HR = 0.57, 95% CI: 0.33–0.99; <i>p</i> = 0.0448). Furthermore, patients with obesity class II had significantly shorter lengths of hospital stays compared with those with normal weight (mean [SE], 6.08 [7.06] vs. 12.50 [19.80] days; <i>p</i> &lt; 0.001).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The obesity paradox survival advantage occurs only in polytrauma patients with obesity class I, whereas these with obesity class II tend to have shorter hospital stays.</p>\u0000 </section>\u0000 </div>","PeriodicalId":215,"journal":{"name":"Obesity","volume":"33 6","pages":"1037-1047"},"PeriodicalIF":4.2,"publicationDate":"2025-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144046686","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to “Alternate-day fasting enhanced weight loss and metabolic benefits over pair-fed calorie restriction in obese mice”","authors":"Steven Swoap,&nbsp;Chloe Henderson,&nbsp;Damian Turner","doi":"10.1002/oby.24298","DOIUrl":"10.1002/oby.24298","url":null,"abstract":"","PeriodicalId":215,"journal":{"name":"Obesity","volume":"33 6","pages":"1019-1020"},"PeriodicalIF":4.2,"publicationDate":"2025-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144015545","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Semaglutide-induced weight loss improves mitochondrial energy efficiency in skeletal muscle","authors":"Ran Hee Choi,&nbsp;Takuya Karasawa,&nbsp;Cesar A. Meza,&nbsp;J. Alan Maschek,&nbsp;Allison M. Manuel,&nbsp;Linda S. Nikolova,&nbsp;Kelsey H. Fisher-Wellman,&nbsp;James E. Cox,&nbsp;Amandine Chaix,&nbsp;Katsuhiko Funai","doi":"10.1002/oby.24274","DOIUrl":"https://doi.org/10.1002/oby.24274","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>Glucagon-like peptide-1 receptor agonists (e.g., semaglutide) potently induce weight loss, thereby reducing obesity-related complications. However, weight regain occurs when treatment is discontinued. An increase in skeletal muscle oxidative phosphorylation (OXPHOS) efficiency upon diet-mediated weight loss has been described, which may contribute to reduced systemic energy expenditure and weight regain. We set out to determine the unknown effect of semaglutide on muscle OXPHOS efficiency.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>C57BL/6J mice were fed a high-fat diet for 12 weeks before receiving semaglutide or vehicle for 1 or 3 weeks. The rates of ATP production and oxygen (O₂) consumption were measured via high-resolution respirometry and fluorometry to determine OXPHOS efficiency in muscle at these two time points.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Semaglutide treatment led to significant reductions in fat and lean mass. Semaglutide improved skeletal muscle OXPHOS efficiency, measured as ATP produced per O₂ consumed in permeabilized muscle fibers. Mitochondrial proteomic analysis revealed changes restricted to two proteins linked to complex III assembly (LYRM7 and TTC19; <i>p</i> &lt; 0.05 without multiple corrections) without substantial changes in the abundance of OXPHOS subunits.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>These data indicate that weight loss with semaglutide treatment increases skeletal muscle mitochondrial efficiency. Future studies could test whether it contributes to weight regain.</p>\u0000 </section>\u0000 </div>","PeriodicalId":215,"journal":{"name":"Obesity","volume":"33 5","pages":"974-985"},"PeriodicalIF":4.2,"publicationDate":"2025-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/oby.24274","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143861626","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unraveling the relationship between head circumference and MC4R deficiency from infancy to adulthood: a case–control study","authors":"Eline E. P. L. van der Walle,&nbsp;Cornelis J. de Groot,&nbsp;Lotte Kleinendorst,&nbsp;Hester de Klerk,&nbsp;Mila S. Welling,&nbsp;Ozair Abawi,&nbsp;Renate E. H. Meeusen,&nbsp;Mariëtte R. Boon,&nbsp;Elisabeth F. C. van Rossum,&nbsp;Mieke M. van Haelst,&nbsp;Erica L. T. van den Akker","doi":"10.1002/oby.24263","DOIUrl":"https://doi.org/10.1002/oby.24263","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>The objective of this study was to investigate head circumference (HC) in patients with melanocortin 4 receptor (MC4R) deficiency, the most common cause of monogenetic obesity.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Patients with (likely) pathogenic <i>MC4R</i> variants were included. HC, height, and weight were measured, and BMI and standard deviation score (SDS) were calculated. HC SDS was compared to the Dutch reference population. Children were matched 1:1 to a control group with common obesity.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Children with MC4R deficiency (<i>n</i> = 63, mean age, 10.32 years) had significantly larger HC (mean, +1.73 SDS) compared to the reference population (0 SDS; <i>p</i> &lt; 0.001) and controls (+1.22 SDS; <i>p</i> = 0.009). In adults (<i>n</i> = 13), HC (median, + 0.86 SDS) did not differ from the reference population (0 SDS; <i>p</i> = 0.152). Macrocephaly (HC ≥ 2 SDS) was present in 43%, 25%, and 23% of pediatric patients with MC4R deficiency, controls, and adult patients, respectively. Children with MC4R deficiency were taller than controls (+1.00 SDS vs. +0.42 SDS; <i>p</i> = 0.016), with similar BMI (+3.99 SDS vs. +3.75 SDS; <i>p</i> = 0.157). HC SDS was associated with height SDS (<i>R</i>², 0.22; <i>p</i> &lt; 0.001) and homeostatic model assessment of insulin resistance (correlation coefficient, 0.542; <i>p</i> &lt; 0.05).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Macrocephaly is a common feature of patients with MC4R deficiency. We recommend measuring HC in patients suspected for genetic obesity, as it can be a clue for MC4R deficiency.</p>\u0000 </section>\u0000 </div>","PeriodicalId":215,"journal":{"name":"Obesity","volume":"33 5","pages":"986-995"},"PeriodicalIF":4.2,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/oby.24263","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143861536","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}